Summary: The GINA 2024 report introduces significant updates to asthma diagnosis and treatment, aligning with the latest research. Key updates include greater emphasis on Peak Expiratory Flow (PEF) measurement for quicker asthma diagnosis, especially in settings with limited access to full diagnostic tests. A more detailed approach is now recommended for "cough-variant asthma," which is challenging to diagnose with minimal changes in lung function tests. The 2024 report introduces the goal of asthma remission, achieved through biological therapy, as a potential treatment objective. Other updates include specific guidelines for drug usage, including cautious use of high-dose inhaled corticosteroids (ICS) and the introduction of combination treatments like LABA and LAMA. The report also highlights the role of immunotherapy and the importance of reducing ICS doses in well-controlled asthma during biological treatment. Additionally, the report discusses the role of rehabilitation, vaccinations, and the need for revised asthma terminology (replacing "mild asthma" with "controlled asthma"). It concludes with recommendations on preventing occupational asthma and improving asthma management.